October 5 – 11, 2026

A Note From the Editor

It was another relatively quiet week in the psychedelics field.

On Monday, however, the U.S. Food and Drug Administration (FDA) announced a request for information (RFI) concerning early-stage ibogaine studies. In doing so, it also floated a potential trial design, telegraphing its thinking on key elements that it might expect to see in any investigational new drug applications.

At ARPA-H’s ASCENT-IBO Proposers’ Day last month, deputy director of FDA’s Division of Psychiatry Bernard Fischer told attendees that the agency was “thinking about how much information we need to put out there to proactively inform the field.” His comments were very well received then, and it appears that the agency has quickly delivered on that intention now. Investigators we spoke with welcomed the move. The RFI is open through November 20th.

Meanwhile, a National Institute of Mental Health grant opportunity that was expected to publish yesterday has yet to appear. The forecasted opportunity, Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs), could provide up to $20 million in aggregate funding across three projects.

Just prior to this week, last Friday, New Mexico’s Department of Health held a public hearing related to its medical psilocybin program, which it hopes to implement by year-end. Key points of contention included a provision that requires landlord consent for psilocybin treatment to take place in a rented home, and a thirty-day window for the department to review patient applications.

I’m grateful for a quieter fortnight, as preparations for The Psychedelic Healthcare Forum in New York City enter their final stages. I hope to see many of you there this Thursday!

Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelic business, policy, research and beyond.

Josh Hardman
Founder & Editor

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Alpha ↗

5 October 2026

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Psychedelic Alpha ↗

8 October 2026

The FDA may soon approve its first psychedelic drug. But how to regulate it?

NBC News ↗

6 October 2026

Synthetic psilocybin company cuts the ribbon on Jersey City office with electeds

Hudson County View ↗

5 October 2026